Salivary malignancies are rare and make up less than 0.3% of all malignancies and 6% of head and neck cancers.About 60–70% of the total stimulated salivary production is derived from the parotids.Approximately 80% of all salivary gland neoplasms originate in the parotid gland.Primary salivary gland tumors are a morphologically diverse group of tumors.There are prognostic indices for predicting the risk of lymph node involvement in salivary gland tumors.Signs and symptoms of salivary gland cancer depend on the location of the primary tumor.Prognostic factors for overall survival include T classification, skin invasion, bone invasion, sex, and age.For locoregional control, several studies have shown tumor size (pathologic T stage), pathologic N stage, tumor grade (high versus not high), use of adjuvant radiotherapy, bone invasion, and close or positive margins to be significant.Surgery remains the mainstay of diagnosis and treatment.Radiotherapy has a key role in preventing locoregional recurrences in high-risk patients.In inoperable and recurrent tumors, fast neutron therapy has shown higher rates of local control, as compared with photon therapy in retrospective and prospective studies. [ABSTRACT FROM AUTHOR]